Literature DB >> 9734471

3-Hydroxy-3-methylglutaryl coenzyme a reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture.

C Guijarro1, L M Blanco-Colio, M Ortego, C Alonso, A Ortiz, J J Plaza, C Díaz, G Hernández, J Egido.   

Abstract

Recent evidence suggests that apoptosis may be involved in the control of vascular smooth muscle cell (VSMC) number in atherosclerotic lesions. 3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors have been reported to induce apoptosis in a variety of tumor cell lines. To evaluate whether these agents also induce apoptosis of VSMCs, cultured rat VSMCs were treated with increasing doses of atorvastatin in the presence of FBS as a survival factor. The presence of apoptosis was evaluated by morphological criteria, annexin V binding, and DNA fragmentation and quantified as the proportion of hypodiploid cells by flow cytometry. Atorvastatin induced apoptosis in a dose-dependent manner, an effect also seen with simvastatin and lovastatin, but not with the hydrophilic drug pravastatin. The proapoptotic effect of statins was seen only when the inhibition of acetate incorporation into sterols was >95% and was fully reversed by mevalonate, farnesyl pyrophosphate, and geranylgeranyl pyrophosphate but not by isopentenyl adenosine, ubiquinone, or squalene, suggesting a role for prenylated proteins in the regulation of VSMC apoptosis. To further assess the role of protein prenylation, VSMCs were exposed to the prenyl transferase inhibitors perillic acid and manumycin A. Both agents induced VSMC apoptosis as evaluated by the above-mentioned criteria. Finally, VSMC treatment with lipophilic statins was associated with decreased prenylation of p21-Rho B, further supporting the role of protein prenylation inhibition in statin-induced VSMC apoptosis. The present data suggest that interference with protein prenylation by HMG-CoA reductase inhibitors or other agents may provide new strategies for the prevention of neointimal thickening.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9734471     DOI: 10.1161/01.res.83.5.490

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  51 in total

Review 1.  Vascular smooth muscle cell apoptosis in atherosclerosis.

Authors:  J J Boyle
Journal:  Int J Exp Pathol       Date:  1999-08       Impact factor: 1.925

Review 2.  Antiinflammatory and immunomodulatory properties of statins.

Authors:  Ora Shovman; Yair Levy; Boris Gilburd; Yehuda Shoenfeld
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

Review 3.  Toxicity of antilipidemic agents: facts and fictions.

Authors:  Antonios M Xydakis; Peter H Jones
Journal:  Curr Atheroscler Rep       Date:  2003-09       Impact factor: 5.113

Review 4.  Scleroderma renal crisis: new insights and developments.

Authors:  Elisa Y Rhew; Walter G Barr
Journal:  Curr Rheumatol Rep       Date:  2004-04       Impact factor: 4.592

Review 5.  Idiopathic pulmonary fibrosis: pathogenesis and therapeutic approaches.

Authors:  Moisés Selman; Victor J Thannickal; Annie Pardo; David A Zisman; Fernando J Martinez; Joseph P Lynch
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 6.  Pleiotropic effects of statins: moving beyond cholesterol control.

Authors:  Paul J Garcia
Journal:  Curr Atheroscler Rep       Date:  2005-02       Impact factor: 5.113

Review 7.  Multifaceted role of Rho proteins in angiogenesis.

Authors:  Sofia D Merajver; Saad Z Usmani
Journal:  J Mammary Gland Biol Neoplasia       Date:  2005-10       Impact factor: 2.673

8.  Role of statins in cerebral vasospasm.

Authors:  T Sugawara; R Ayer; J H Zhang
Journal:  Acta Neurochir Suppl       Date:  2008

9.  Cell-specific toxicity of fibrates in human embryonal rhabdomyosarcoma cells.

Authors:  Takayoshi Maiguma; Koji Fujisaki; Yoshinori Itoh; Kazutaka Makino; Daisuke Teshima; Fumi Takahashi-Yanaga; Toshiyuki Sasaguri; Ryozo Oishi
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-02-08       Impact factor: 3.000

10.  Atorvastatin accelerates extracellular nucleotide degradation in human endothelial cells.

Authors:  Lana Osman; Mohamed Amrani; Charles Ilsley; Magdi H Yacoub; Ryszard T Smolenski
Journal:  Mol Cell Biochem       Date:  2007-12-25       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.